Impressive response to 177Lu-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer refractory to apalutamide, docetaxel and metastasis-directed therapy
https://doi.org/10.17650/1726-9776-2024-20-4-98-103
Abstract
PSMA-targeted radionuclide therapy (PSMA – prostate-specific membrane antigen) based on the theranostic concept of “treat what we see and see what we treat” has proven to be a highly effective therapeutic modality for metastatic castration-resistant prostate cancer (mCRPC). We present an illustrative case of the effectiveness and prospects of this therapy in mCRPC. The patient aged 84 years underwent external beam radiation therapy (EBRT) to the prostate area, seminal vesicles, and regional lymph nodes at the stage of locally advanced prostate cancer (cT3aN1M0, stage IV). After 28 months of androgen deprivation therapy, castration-resistant stage of the disease was registered with multiple metastases in the bones and pelvic lymph nodes. In combination with ongoing androgen deprivation therapy, the following treatments were sequentially performed: metastasis-directed therapy through stereotactic radiotherapy to the bone lesions, apalutamide in combination with stereotactic radiotherapy to the bone and lymph node lesions, and 5 courses of docetaxel chemotherapy. Time to progression with these therapies did not exceed 6 months. From December 2022 to May 2023, 177Lu-PSMA-617 PSMA-targeted therapy was performed (4 courses with an interval of 6–8 weeks, average therapeutic activity 7.6 GBq). Treatment was suspended due to development of complete radiologic response and the absence of metabolic substrate for continuation of therapy as well as total prostate-specific antigen decrease from 17 ng/mL (December of 2022) to 0.01 ng/mL (June of 2023). Among the adverse effects, the development of grade 1 xerostomia was noted. At the follow-up examination in March 2024, ECOG (Eastern Cooperative Oncology Group) score was 0, total prostate-specific antigen level was 0.05 ng/mL, complete radiologic response according to positron emission tomography/computed tomography with 18F-PSMA-1007 was registered, time without progression was 15 months. Therefore, PSMA-targeted radioligand therapy with 177Lu-PSMA-617 was highly effective with low toxicity in an elderly patient with mCRPC refractory to standard drug therapy.
About the Authors
A. A. LiRussian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
T. M. Geliashvili
Russian Federation
Tamara M. Geliashvili.
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
A. A. Rumyantsev
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
A. I. Pronin
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
A. S. Krylov
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
O. D. Baranova
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
A. V. Parnas
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
V. S. Ilyakov
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
Competing Interests:
None
D. A. Vorobyeva
Russian Federation
Build. 1, 20 Delegatskaya St., Moscow 127473
Competing Interests:
None
References
1. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834
2. Shakhzadova A.O., Starinsky V.V., Lisichnikova I.V. Cancer care to the population of Russia in 2022. Sibirskiy oncologicheskiy zhurnal = Siberian Journal of Oncology 2023;22(5):5–13. (In Russ.). DOI: 10.21294/1814-4861-2023-22-5-5-13.
3. State of oncological care in Russia in 2022. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. 239 p. (In Russ.).
4. Kirby M., Hirst C., Crawford E.D. Characterising the castration- resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92. DOI: 10.1111/j.1742-1241.2011.02799.x
5. Hofman M.S., Hicks R.J., Maurer T., Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018;38(1):200–17. DOI: 10.1148/rg.2018170108
6. Sartor O., de Bono J., Chi K.N. et al.; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091–103. DOI: 10.1056/NEJMoa2107322
7. Fallah J., Agrawal S., Gittleman H. et al. FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023;29(9):1651–7. DOI: 10.1158/1078-0432.CCR-22-2875
Review
For citations:
Li A.A., Geliashvili T.M., Rumyantsev A.A., Pronin A.I., Krylov A.S., Baranova O.D., Parnas A.V., Ilyakov V.S., Vorobyeva D.A. Impressive response to 177Lu-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer refractory to apalutamide, docetaxel and metastasis-directed therapy. Cancer Urology. 2024;20(4):98-103. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-4-98-103